Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization -

- Completed enrollment in the Phase 3 APPROACH pivotal study of HLP003 in Major Depressive Disorder (“MDD”); topline data remain on track for Q4 2026(1)(,)(2) -